Ligand Pharmaceuticals Incorporated reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 32.87 million compared to USD 59.22 million a year ago. Net loss was USD 12.79 million compared to net income of USD 0.404 million a year ago. Basic loss per share from continuing operations was USD 0.74 compared to basic earnings per share from continuing operations of USD 0.57 a year ago. Diluted loss per share from continuing operations was USD 0.74 compared to diluted earnings per share from continuing operations of USD 0.56 a year ago. Basic loss per share was USD 0.74 compared to basic earnings per share of USD 0.02 a year ago. Diluted loss per share was USD 0.74 compared to diluted earnings per share of USD 0.02 a year ago.
For the nine months, revenue was USD 103.21 million compared to USD 145.86 million a year ago. Net income was USD 31.45 million compared to net loss of USD 15.88 million a year ago. Basic earnings per share from continuing operations was USD 1.92 compared to USD 0.55 a year ago. Diluted earnings per share from continuing operations was USD 1.86 compared to USD 0.54 a year ago. Basic earnings per share was USD 1.82 compared to basic loss per share of USD 0.94 a year ago. Diluted earnings per share was USD 1.77 compared to diluted loss per share of USD 0.93 a year ago.